Intercept Pharmaceuticals
Manufacturing · New Jersey, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
305 Madison Ave, Morristown, New Jersey,...Phone Number
(646) 747-1000Website
www.interceptpharma.comRevenue
$101.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
6
6
1
1
1
1
About Intercept Pharmaceuticals
Intercept Pharmaceuticals operates as a biopharmaceutical company specializing in the development and commercialization of therapeutics targeting liver diseases. The company focuses on addressing significant unmet medical needs within hepatology through targeted drug development and clinical research initiatives. By concentrating its efforts on liver-related conditions, Intercept has built a specialized expertise in understanding disease mechanisms and developing treatment approaches that address complex pathophysiology in this therapeutic area. The company's research and development efforts center on identifying novel mechanisms of action and advancing compounds through clinical development stages. Intercept's approach combines rigorous scientific investigation with a commitment to understanding the underlying biology of liver diseases, enabling the organization to pursue therapeutic candidates with meaningful clinical potential. This focused strategy has allowed the company to develoRead more
Intercept Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Intercept Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Intercept Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Intercept Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Intercept Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Intercept Pharmaceuticals
Intercept Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Intercept Pharmaceuticals is spiking on competitors!
Earning: See what the market has to say on Intercept Pharmaceuticals recently announced quarterly report
Funding: Get notified immidiatlly once Intercept Pharmaceuticals has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Intercept Pharmaceuticals
Compare insights from companies similar to Intercept Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Intercept Pharmaceuticals
$101.3M
201-500
Private
$1.5B
2002
WW
William WallaceChief Information Officer
Company Profile Activity
Activity Insights
Intercept Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Intercept Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Intercept Pharmaceuticals.
Intercept Pharmaceuticals financials insights
Gather financial insights about Intercept Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Series B
$25M
2012
Series C
$30M
Stock Offering
$75M
2013
Stock Offering
$61.7M
2014
Stock Offering
$183.3M
2016
Debt
$447.7M
2018
Stock Offering
$250M
2019
Stock Offering
$200M
Debt
$210.4M
Intercept Pharmaceuticals Tech Stack
A closer look at the technologies used by Intercept Pharmaceuticals
See more technologies
Most Recent Scoops
Person-Based
Project
Laboratory Operations, Medical Research, Clinical Operations
Hiring Plans
Intercept Pharmaceuticals has more open roles in Sales than it has had at any time in the past 12 months.
Hiring Plans
Layoffs
Layoffs
Person-Based
Intercept Pharmaceuticals News & Media
Intercept Announces Voluntary Withdrawal of OCALIVA® for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold
MORRISTOWN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced its decision to voluntarily withdraw OCALIVA® (obeticholic acid) from the US market for the treatment of primary biliary cholangitis (PBC), a rare, progressive liver disease. This decision follows a request from the US Food and Drug Administration (FDA). In addition, FDA has placed a clinical hold on all Intercept clinical trials cIntercept Announces Data to be Presented at Digestive Disease Week 2025
Abstracts include a presidential plenary-selected Phase 2 study evaluating the combination of obeticholic acid and bezafibrate in PBC, along with 10 other abstracts Abstracts include a presidential plenary-selected Phase 2 study evaluating the combination of obeticholic acid and bezafibrate in PBC, along with 10 other abstractsIntercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA)
MORRISTOWN, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) that addresses the supplemental New Drug Application (sNDA) for OCALIVA® (obeticholic acid, OCA) seeking full approval for the treatment of indicated patients with primary biliary cholangitis (PBC) – a rare, progressive disease that dispropoIntercept Provides Regulatory Update Regarding sNDA for OCALIVA
MORRISTOWN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned subsidiary of Alfasigma S.p.A., today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it is continuing its review of the supplemental New Drug Application (sNDA) for full approval of OCALIVA® (obeticholic acid, OCA) for the treatment of indicated patients with primary biliary cholangitis (PBC), and its action under the Prescription Drug User Fee Act (PDUFA)
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Intercept Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Intercept Pharmaceuticals operates as a biopharmaceutical company specializing in the development and commercialization of therapeutics targeting liver diseases. The company focuses on addressing significant unmet medical needs within hepatology through targeted drug development and clinical research initiatives. By concentrating its efforts on liv... Read More
